SWITCH SWEDEHEART
2026
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome — a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry (SWITCH SWEDEHEART)
In 17,095 patients with an acute coronary syndrome, prasugrel as the default P2Y12 inhibitor did not reduce death, myocardial infarction or stroke at 1 year compared with ticagrelor.
Result
Efficacy: Cumulative 1-year risk of the composite of death, myocardial infarction or strokeadjusted OR 0.90 (95% CI 0.77-1.06)
Safety: Major bleedingOR 0.80 (95% CI 0.64-0.99)
Below 1 favours prasugrel as the default P2Y12 inhibitor, above 1 favours ticagrelor.
Event rates Prasugrel as the default P2Y12 inhibitor 11.1% vs ticagrelor 11.8% (cumulative 1-year risk of the composite of death, myocardial infarction or stroke)
Also reported: No difference in the individual components.
- Subtopic
- P2Y12 inhibitor choice
- Design
- Registry-based (SWEDEHEART), prospective, multicentre, open-label, stepped-wedge cluster-randomised trial; Swedish administrative regions form the clusters; all clusters start with ticagrelor as the default P2Y12 inhibitor and the order in which clusters switch to prasugrel as default is randomly assigned, one cluster switching every 9 months; outcomes captured through national registries with 1-year follow-up
- Relevance
- Important: one of several pillars.
- Source
- Omerovic E, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2609057
Discussion & critique
A stepped-wedge registry trial tests a regional default, not a drug in an individual patient, and that is its strength: 17,095 consecutive patients including the elderly, prior stroke and an indication for anticoagulation, the people conventional antiplatelet trials exclude. The ischaemic composite is neutral and its interval spans a 23% reduction to a 6% increase. The bleeding advantage is the finding people will quote, and its upper bound is 0.99: one event either way and it disappears.